Outset Medical, Inc.
No enriched coverage for $OM in the last 7 days.
No SEC Form 4 filings for $OM in the last 30 days.
See all $OM insider activity →Analysts updated ratings and price targets for Canadian companies. Aya Gold & Silver (AYA:CA) saw a target raise to $56.00. Banyan Gold (BYN:CA) initiated with a $3.00 target. D2L (DTOL:CA) was downgraded to Neutral. Empire Company (EMP.A:CA) had mixed target adjustments. Groupe Dynamite (GRGD:CA) received varied target changes. Transat A.T. (TRZ:CA) saw multiple target cuts.
Outset Medical, Inc. (OM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 27, 2026, John Brottem informed Outset Medical, Inc. (the “Company”) of his decision to depart from the Company a
Outset Medical (OM) reported Q2 2026 revenue of $31.6 million, up 1% year over year and 14% sequentially. Console revenue was $9.5 million, up 6% YoY, while product revenue fell 5% to $21.9 million. Non-GAAP gross margin was 42.2%. Cash and investments were $151 million. Full-year revenue guidance is $125 million to $130 million.
Recent OM coverage spans financial news, earnings and corporate actions.
No rating change, limited impact.
Departure of a senior legal officer may cause short‑term uncertainty but no immediate financial impact.
The earnings call provides fresh operating datapoints (revenue, margins, cash use) and a new contracted backlog catalyst via HCA, supporting near-term sentiment and model updates.
The quarter showed margin expansion and cash burn, while the HCA three-year $40M refresh deal supports backlog visibility and potential adoption.
This is a disclosed ownership update by a major asset manager, but it does not provide a new operational catalyst for Outset Medical.
AlphAI scores every news story that mentions OM with an AI model for sentiment and relevance, and aggregates insider trades from Outset Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts updated ratings and price targets for Canadian companies. Aya Gold & Silver (AYA:CA) saw a target raise to $56.00. Banyan Gold (BYN:CA) initiated with a $3.00 target. D2L (DTOL:CA) was downgraded to Neutral. Empire Company (EMP.A:CA) had mixed target adjustments. Groupe Dynamite (GRGD:CA) received varied target changes. Transat A.T. (TRZ:CA) saw multiple target cuts.
2 min readOutset Medical, Inc. (OM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 27, 2026, John Brottem informed Outset Medical, Inc. (the “Company”) of his decision to depart from the Company a
1 min readOutset Medical (OM) reported Q2 2026 revenue of $31.6 million, up 1% year over year and 14% sequentially. Console revenue was $9.5 million, up 6% YoY, while product revenue fell 5% to $21.9 million. Non-GAAP gross margin was 42.2%. Cash and investments were $151 million. Full-year revenue guidance is $125 million to $130 million.
6 min readOutset Medical, Inc. (OM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Outset Medical Reports Second Quarter 2026 Results San Jose, CA – August 6, 2026 – Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today
6 min readBlackRock, Inc. filed an amended Schedule 13G for Outset Medical, Inc., reporting beneficial ownership of 365,556 shares of Outset Medical common stock, or 2.0% of the outstanding class. BlackRock reported sole voting and sole dispositive power over the shares, with no shared voting or dispositive power.
2 min readNational Bank Financial analysts revised precious-metals and copper forecasts ahead of Q2 earnings, citing realized gold at $4,508/oz and silver at $73/oz, and copper at $5.82/lb. They cut 2026 gold and silver assumptions and adjusted target prices for multiple miners, generally lower. TD Cowen upgraded First Quantum Minerals on a likely Cobre Panama restart by year-end.
7 min readOsisko Metals (TSX: OM) said Glencore Canada converted its US$25 million senior secured convertible debenture into 88,962,500 units at C$0.40 per unit, plus interest conversion into 6,862,444 units at C$1.58 per unit. Glencore Canada also exercised warrants cashlessly, issuing 32,301,860 shares. TSX approval remains pending.
3 min readOutset Medical (Nasdaq: OM) said its Compensation Committee approved inducement equity awards under Nasdaq Rule 5635(c)(4) for three newly hired employees: 4,000 RSUs to one non-executive, and 10,000 PSUs plus 24,000 PSUs to another non-executive and EVP Derick Elliott. RSUs vest over three years; PSUs depend on 2026 performance goals.
2 min readOutset Medical, Inc. (OM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-10.1 2 om-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THA
3 min readOsisko Metals (TSX: OM) began its 2026 drilling at the Gaspé copper project in Quebec, aiming to add mineralization within the planned Whittle pit. It reported hole 30-1196: 80m at 1.93% Cu from 196m, including 30m at 3.49% Cu from 224m. Scotia Capital said intercepts fall in modelled waste rock, potentially supporting resource conversion.
4 min read
